Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Homologous and Heterologous Covid-19 Booster Vaccinations
Robert L. Atmar, Kirsten E. Lyke, Meagan E. Deming, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 11, pp. 1046-1057
Open Access | Times Cited: 532

Showing 1-25 of 532 citing articles:

Humoral and cellular immune memory to four COVID-19 vaccines
Zeli Zhang, José Mateus, Camila H. Coelho, et al.
Cell (2022) Vol. 185, Iss. 14, pp. 2434-2451.e17
Open Access | Times Cited: 444
Covid-19 Vaccines — Immunity, Variants, Boosters
Dan H. Barouch
New England Journal of Medicine (2022) Vol. 387, Iss. 11, pp. 1011-1020
Open Access | Times Cited: 378
Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review
Santenna Chenchula, Padmavathi Karunakaran, Sushil Sharma, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 2969-2976
Open Access | Times Cited: 294
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
David Goldblatt, Galit Alter, Shane Crotty, et al.
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 6-26
Open Access | Times Cited: 233
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Alessandro Sette, Shane Crotty
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 27-46
Open Access | Times Cited: 214
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 166
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, et al.
BMJ (2022), pp. e072141-e072141
Open Access | Times Cited: 162
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Kirsten E. Lyke, Robert L. Atmar, Clara Domínguez Islas, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 7, pp. 100679-100679
Open Access | Times Cited: 144
The humoral response and antibodies against SARS-CoV-2 infection
Hai Qi, Bo Liu, Xinquan Wang, et al.
Nature Immunology (2022) Vol. 23, Iss. 7, pp. 1008-1020
Open Access | Times Cited: 144
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 7, pp. 689-699
Open Access | Times Cited: 133
Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada
Danuta M. Skowronski, Yossi Febriani, Manale Ouakki, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 11, pp. 1980-1992
Open Access | Times Cited: 119
T Cell Responses to SARS-CoV-2
Alessandro Sette, John Sidney, Shane Crotty
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 343-373
Closed Access | Times Cited: 114
Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment
Yujing Huang, Xiaohan Guo, Yi Wu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 109
Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses
Jeroen M. J. Tas, Jahyun Koo, Ying‐Cing Lin, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1856-1871.e6
Open Access | Times Cited: 99
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice
Baoling Ying, Suzanne M. Scheaffer, Bradley Whitener, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1572-1587.e11
Open Access | Times Cited: 89
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 88
Animal models for COVID-19: advances, gaps and perspectives
Changfa Fan, Yong Wu, Rui Xiong, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 79
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
V. Edwin Hillary, Stanislaus Antony Ceasar
Heliyon (2023) Vol. 9, Iss. 3, pp. e13952-e13952
Open Access | Times Cited: 76
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study
Susana Monge, Ayelén Rojas‐Benedicto, Carmen Olmedo, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 9, pp. 1313-1320
Open Access | Times Cited: 72
Vaccine protection against the SARS-CoV-2 Omicron variant in macaques
Abishek Chandrashekar, Jingyou Yu, Katherine McMahan, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1549-1555.e11
Open Access | Times Cited: 71
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 4, pp. 351-360
Closed Access | Times Cited: 41
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
Komal Srivastava, Juan Manuel Carreño, Charles Gleason, et al.
Immunity (2024) Vol. 57, Iss. 3, pp. 587-599.e4
Open Access | Times Cited: 34
Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis
Xiaodi Wu, Ke Xu, Ping Zhan, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 14
An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants
Fábio Mambelli, Ana Carolina V. S. C. de Araujo, Jéssica Pires Farias, et al.
Pathogens (2025) Vol. 14, Iss. 1, pp. 23-23
Open Access | Times Cited: 1
Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters
Ricardo da Silva Antunes, Vicente Fajardo-Rosas, Esther Dawen Yu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top